Akari Therapeutics Q1 net loss $3.7M, cash $2.6M; advances ADC pipeline

Akari Therapeutics Plc

2025-Q1 EPS reported $0.00

Net loss from operations $3.7M in Q1 2025 vs $5.6M in Q1 2024; R&D spend down to $0.8M.
Cash $2.6M as of March 31, 2025; March 2025 offering netted $6.0M, $4.0M received in April.
Appointed Mark Kubik as Head of Business Development, Oncology to strengthen ADC expertise.
Expects to present preclinical data for PH1-payload ADC at a scientific conference in H2 2025.
Pipeline lead AKTX-101 (Trop2/PH1 ADC) advancing; out-licensing non-core assets for non-dilutive capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.